|PRINT ISSN : 2319-7692
Online ISSN : 2319-7706
Issues : 12 per year
Publisher : Excellent Publishers
Email : email@example.com / firstname.lastname@example.org
Index Copernicus ICV 2015: 85.95
NAAS RATING 2017: 5.38
Psoriasis is a common chronic inflammatory skin disease affecting up to 2–3% of the population worldwide. Interleukin-33 is a recently discovered cytokine and one of the newest members that belongs to the IL-1 super-family inflammatory cytokines and is mainly expressed by different types of structural cells. IL-33 is considered an alarm molecule due to its release after necrosis or tissue damage. Psoriasis is associated with chronic inflammation and it often coexists with inflammatory arthritis in which IL-33 has been implicated. Assessment of serum IL-33 levels in psoriatic patients of different types and invistigate its correlation to the severity and extent of psoriasis.It is a case-control study, serum IL-33 levels were assessed by using commercial enzyme-linked immunosorbent assay kits (ELISA) in 40 psoriatic patients of different types (group I) and 30 apparaently healthy subjects as control (group II) with matched age and sex. A significant difference in IL-33 serum levels between patients and control was detected. Also positive correlation between IL-33 and Psoraisis Area and Sevirity Index (PASI) was detected. IL-33 could be considered as a reliable marker among different types of psoriasis and disease severity.